title: Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).
authors.forename: J N
authors.initials: JN
authors.lastname: Bastie
authors.forename: F
authors.initials: F
authors.lastname: Suzan
authors.forename: I
authors.initials: I
authors.lastname: Garcia
authors.forename: F
authors.initials: F
authors.lastname: Isnard
authors.forename: T
authors.initials: T
authors.lastname: de Revel
authors.forename: C
authors.initials: C
authors.lastname: Terre
authors.forename: D
authors.initials: D
authors.lastname: Mayeur
authors.forename: C
authors.initials: C
authors.lastname: Abraham
authors.forename: R
authors.initials: R
authors.lastname: Lavielle
authors.forename: S
authors.initials: S
authors.lastname: Castaigne
mesh_terms: D000328:Adult; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D000079982:Gemtuzumab; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab